Phenytoin and carbamazepine cross reactivity: Report of a case and review of literature

Postgraduate Medical Journal

Volumn 79, Issue 938, 2003, Pages 703-704

  Misra, U K ^a   Kalita, J ^a   Rathore, C ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG DERIVATIVE; OXCARBAZEPINE; PHENYTOIN; VALPROIC ACID;

BLOOD CELL COUNT; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CROSS REACTION; DISEASE COURSE; DRUG ERUPTION; DRUG INTERACTION; FEVER; FOCAL EPILEPSY; HUMAN; IATROGENIC DISEASE; LYMPHADENOPATHY; MALE; MEDICAL LITERATURE; MOUTH ULCER; PHYSICAL EXAMINATION; PRESCRIPTION; PRURITUS; RASH; REVIEW; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; ULCER; URINALYSIS;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; DRUG ERUPTIONS; DRUG INTERACTIONS; HUMANS; MALE; ORAL ULCER; PHENYTOIN; SEIZURES;

EID: 1642496963     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995;74:144-51.
2. Abbondanzo SL, Irey NS, Frizzera G. Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns. Am J Surg Pathol 1995;19:675-86.
3. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
4. Sinnige HA, Boender CA, Kuypers EW, et al. Carbamazepine induced pseudolymphoma and immune dysregulation. J Intern Med 1984;227:355-8.
5. Bateman DE. Carbamazepine induced systemic lupus erythematosus: case report. BMJ 1985;291:632-3.
6. Eames P. Adverse reactions to carbamazepine managed by desensitization. Lancet 1989;i:509-10.
7. Coope R, Burrows RGR. Treatment of epilepsy with sodium diphenylhydantoin. Lancet 1940;i:490-2.
8. Mc Carthy LJ, Aguilar JC. Fatal benign phenytoin hypersensitivity [letter]. Lancet 1977;ii:932.
9. Greene DA. Localized cervical lymphadenopathy induced by diphenylhydantoin sodium. Arch Otolaryngol 1975;101:446-8.
10. Smith H, Newton R. Adverse reaction to carbamazepine managed by desensitation. Lancet 1985;i:753.
11. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988;82:1826-32.
12. Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
13. Gerson WT, Fine DG, Spielberg SP, et al. Anticonvulsant induced aplastic anemia: increased susceptibility to toxic drug metabolities in vitro. Blood 1983;61:889-93.
14. De Swert LF, Ceuppens JL, Teuwen D, et al. Acute interstitial pneumonitis and carbamazepine therapy. Acta Paediatr Scand 1984;73:285-8.
15. Furst S, Uetrecht JP. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol 1993;45:1267-75.
16. Morrow J. The pharmakokinetics of the individual antiepileptic drugs. In: Dam M, ed. A practical approach to epilepsy. Oxford: Pergamon Press, 1991:88-104.
17. Beran RG. Cross reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993;34:163-5.